Heritage Labs, INC.

Heritage Labs, INC. was paid $2.32M by Medicaid between Dec 2018 and Dec 2024, across 69 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 31% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#23 of 108

Median peer was paid$588K

This provider vs. median3.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	32	$266.50
2019	2,666	$20K
2020	3,102	$25K
2021	5,043	$220K
2022	16,424	$620K
2023	14,971	$392K
2024incomplete	20,605	$1.04M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	31%	11,811	7,856	$727K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	21%	7,990	6,644	$477K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	18%	12,353	8,180	$413K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.7%	6,751	5,606	$132K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	5.0%	941	871	$115K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	3.0%	1,572	1,323	$70K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.5%	1,262	1,114	$57K
87631		1.6%	390	377	$37K
87481		1.5%	382	363	$34K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.3%	648	557	$31K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.0%	650	547	$23K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	231	216	$22K

57 more codes

87653		<1%	675	$14K
80053	Comprehensive metabolic panel	<1%	1,957	$14K
81514		<1%	108	$13K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	535	$12K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	533	$11K
87563		<1%	483	$11K
84443	Thyroid stimulating hormone (TSH)	<1%	970	$10K
80061	Lipid panel	<1%	1,144	$9K
87641		<1%	358	$8K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	443	$8K
87640		<1%	367	$8K
87529		<1%	161	$7K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,326	$7K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,048	$6K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	472	$6K
87500		<1%	312	$6K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	300	$5K
82607		<1%	539	$5K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	3,268	$3K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	88	$3K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	163	$2K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	82	$2K
86769		<1%	42	$1K
87511		<1%	58	$1K
85027		<1%	210	$998.57
82728		<1%	119	$934.74
86803		<1%	93	$925.95
85007		<1%	392	$874.92
81001		<1%	425	$813.29
84439		<1%	112	$677.86
87086	Culture, bacterial; quantitative colony count, urine	<1%	118	$621.24
83735		<1%	145	$612.57
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	32	$480.00
84481		<1%	26	$312.18
83540		<1%	60	$182.44
84153		<1%	13	$140.91
86780		<1%	14	$126.88
86593		<1%	32	$90.98
82746		<1%	12	$87.64
81003		<1%	52	$75.45
82465		<1%	21	$47.34
84100		<1%	14	$29.66
80048	Basic metabolic panel (calcium, ionized)	<1%	12	$15.35
82310		<1%	39	$8.54
82565		<1%	40	$8.48
84520		<1%	39	$6.56
84460		<1%	36	$4.39
84075		<1%	36	$4.29
84450		<1%	36	$4.29
82247		<1%	36	$4.16
82040		<1%	36	$4.10
84132		<1%	40	$3.94
84155		<1%	36	$3.04
82435		0%	39	$0.00
82374		0%	39	$0.00
84295		0%	40	$0.00
82947		0%	36	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKIMINAIA, NAMEER (COO)